Knoernschild, Kevin
Johnson, Hans J.
Schroeder, Kimberly E.
Swier, Vicki J.
White, Katherine A.
Sato, Takashi S.
Rogers, Christopher S.
Weimer, Jill M.
Sieren, Jessica C. http://orcid.org/0000-0002-1109-7886
Funding for this research was provided by:
Noah's Hope and Hope 4 Bridget
Article History
Received: 29 September 2022
Accepted: 22 March 2023
First Online: 29 March 2023
Competing interests
: C.S.R. is an employee of Precigen Exemplar, a company commercializing the CLN2 porcine model. J.M.W. has equity in Amicus Therapeutics, a biotechnology company focused on developing medicines for people with rare metabolic diseases. All other authors have no competing interests.